| Dr Brian D Heeringa, MD | |
|
880 Munson Ave, Suite A, Traverse City, MI 49686-3661 | |
| (231) 946-1488 | |
| (231) 946-1489 |
| Full Name | Dr Brian D Heeringa |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 25 Years |
| Location | 880 Munson Ave, Traverse City, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497789010 | NPI | - | NPPES |
| 4759050 | Medicaid | MI | |
| 020H310060 | Other | BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | BH076613 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brian D Heeringa Pc | 7315256922 | 2 |
News Archive
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that its Korean distributor, BR Holdings, received marketing clearance from the Korean Food & Drug Administration (KFDA) to market Mazor's Renaissance system.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
Columbia Laboratories, Inc. has repurchased 3,333,330 shares of its Common Stock, par value $0.01 per share, from investment funds for which Perry Corp. or an affiliate acts as investment advisor and/or general partner at $0.90 per share for an aggregate total purchase price of approximately $3 million. This transaction reduces the total issued and outstanding shares of Common Stock by about 4% from approximately 84.1 million to 80.8 million. This transaction also reduces the Company's previously forecast 2010 year-end cash balance to approximately $20 million.
Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.
THE Welsh Ambulance Service has issued a fresh plea for the public to use 999 responsibly as Christmas draws near.
› Verified 4 days ago
| Entity Name | Munson Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083761860 PECOS PAC ID: 3072426287 Enrollment ID: O20040108000904 |
News Archive
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that its Korean distributor, BR Holdings, received marketing clearance from the Korean Food & Drug Administration (KFDA) to market Mazor's Renaissance system.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
Columbia Laboratories, Inc. has repurchased 3,333,330 shares of its Common Stock, par value $0.01 per share, from investment funds for which Perry Corp. or an affiliate acts as investment advisor and/or general partner at $0.90 per share for an aggregate total purchase price of approximately $3 million. This transaction reduces the total issued and outstanding shares of Common Stock by about 4% from approximately 84.1 million to 80.8 million. This transaction also reduces the Company's previously forecast 2010 year-end cash balance to approximately $20 million.
Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.
THE Welsh Ambulance Service has issued a fresh plea for the public to use 999 responsibly as Christmas draws near.
› Verified 4 days ago
| Entity Name | Munson Healthcare Charlevoix Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326124058 PECOS PAC ID: 4284528035 Enrollment ID: O20040211001170 |
News Archive
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that its Korean distributor, BR Holdings, received marketing clearance from the Korean Food & Drug Administration (KFDA) to market Mazor's Renaissance system.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
Columbia Laboratories, Inc. has repurchased 3,333,330 shares of its Common Stock, par value $0.01 per share, from investment funds for which Perry Corp. or an affiliate acts as investment advisor and/or general partner at $0.90 per share for an aggregate total purchase price of approximately $3 million. This transaction reduces the total issued and outstanding shares of Common Stock by about 4% from approximately 84.1 million to 80.8 million. This transaction also reduces the Company's previously forecast 2010 year-end cash balance to approximately $20 million.
Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.
THE Welsh Ambulance Service has issued a fresh plea for the public to use 999 responsibly as Christmas draws near.
› Verified 4 days ago
| Entity Name | Kalkaska Memorial Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013183060 PECOS PAC ID: 3577536002 Enrollment ID: O20040813000668 |
News Archive
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that its Korean distributor, BR Holdings, received marketing clearance from the Korean Food & Drug Administration (KFDA) to market Mazor's Renaissance system.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
Columbia Laboratories, Inc. has repurchased 3,333,330 shares of its Common Stock, par value $0.01 per share, from investment funds for which Perry Corp. or an affiliate acts as investment advisor and/or general partner at $0.90 per share for an aggregate total purchase price of approximately $3 million. This transaction reduces the total issued and outstanding shares of Common Stock by about 4% from approximately 84.1 million to 80.8 million. This transaction also reduces the Company's previously forecast 2010 year-end cash balance to approximately $20 million.
Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.
THE Welsh Ambulance Service has issued a fresh plea for the public to use 999 responsibly as Christmas draws near.
› Verified 4 days ago
| Entity Name | Munson Healthcare Grayling |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710383351 PECOS PAC ID: 2062736655 Enrollment ID: O20150326000110 |
News Archive
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that its Korean distributor, BR Holdings, received marketing clearance from the Korean Food & Drug Administration (KFDA) to market Mazor's Renaissance system.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
Columbia Laboratories, Inc. has repurchased 3,333,330 shares of its Common Stock, par value $0.01 per share, from investment funds for which Perry Corp. or an affiliate acts as investment advisor and/or general partner at $0.90 per share for an aggregate total purchase price of approximately $3 million. This transaction reduces the total issued and outstanding shares of Common Stock by about 4% from approximately 84.1 million to 80.8 million. This transaction also reduces the Company's previously forecast 2010 year-end cash balance to approximately $20 million.
Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.
THE Welsh Ambulance Service has issued a fresh plea for the public to use 999 responsibly as Christmas draws near.
› Verified 4 days ago
| Entity Name | Brian D Heeringa Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023486867 PECOS PAC ID: 7315256922 Enrollment ID: O20151022000546 |
News Archive
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that its Korean distributor, BR Holdings, received marketing clearance from the Korean Food & Drug Administration (KFDA) to market Mazor's Renaissance system.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
Columbia Laboratories, Inc. has repurchased 3,333,330 shares of its Common Stock, par value $0.01 per share, from investment funds for which Perry Corp. or an affiliate acts as investment advisor and/or general partner at $0.90 per share for an aggregate total purchase price of approximately $3 million. This transaction reduces the total issued and outstanding shares of Common Stock by about 4% from approximately 84.1 million to 80.8 million. This transaction also reduces the Company's previously forecast 2010 year-end cash balance to approximately $20 million.
Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.
THE Welsh Ambulance Service has issued a fresh plea for the public to use 999 responsibly as Christmas draws near.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian D Heeringa, MD 880 Munson Ave, Suite A, Traverse City, MI 49686-3661 Ph: (231) 946-1488 | Dr Brian D Heeringa, MD 880 Munson Ave, Suite A, Traverse City, MI 49686-3661 Ph: (231) 946-1488 |
News Archive
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that its Korean distributor, BR Holdings, received marketing clearance from the Korean Food & Drug Administration (KFDA) to market Mazor's Renaissance system.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
Columbia Laboratories, Inc. has repurchased 3,333,330 shares of its Common Stock, par value $0.01 per share, from investment funds for which Perry Corp. or an affiliate acts as investment advisor and/or general partner at $0.90 per share for an aggregate total purchase price of approximately $3 million. This transaction reduces the total issued and outstanding shares of Common Stock by about 4% from approximately 84.1 million to 80.8 million. This transaction also reduces the Company's previously forecast 2010 year-end cash balance to approximately $20 million.
Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.
THE Welsh Ambulance Service has issued a fresh plea for the public to use 999 responsibly as Christmas draws near.
› Verified 4 days ago
Dr. Adam Bryant Smith, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 4977 Skyview Ct, Traverse City, MI 49684 Phone: 231-421-6599 Fax: 231-421-6602 | |
Dr. James R Mcdonnell, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1221 6th St, Ste 208, Traverse City, MI 49684 Phone: 231-935-2844 Fax: 231-935-2850 | |
Christopher Ammond Lafond, M.D., M.P.H. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1221 Sixth St Ste. 300, Traverse City, MI 49684 Phone: 231-935-2400 Fax: 231-935-2424 | |
Walter Channing Noble, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 1221 Sixth St Ste 300, Traverse City, MI 49684 Phone: 231-935-2400 Fax: 231-935-2424 | |
Dr. Shruti Sevak, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1221 Sixth St Ste 300, Traverse City, MI 49684 Phone: 231-935-2400 Fax: 231-935-2424 | |
Dr. Steven D Rimar, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3930 Cedar Run Rd, Traverse City, MI 49684 Phone: 231-935-0390 | |
Lauren Cardella, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 3930 Cedar Run Rd, Traverse City, MI 49684 Phone: 231-935-0390 Fax: 231-935-0395 |